EP2890362A2 - Chlorhexidine gluconate solubilized in a hydrophobic monoacylglyceride - Google Patents
Chlorhexidine gluconate solubilized in a hydrophobic monoacylglycerideInfo
- Publication number
- EP2890362A2 EP2890362A2 EP13759935.3A EP13759935A EP2890362A2 EP 2890362 A2 EP2890362 A2 EP 2890362A2 EP 13759935 A EP13759935 A EP 13759935A EP 2890362 A2 EP2890362 A2 EP 2890362A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- monoacylglyceride
- composition
- weight
- chg
- chlorhexidine gluconate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 33
- 229960003333 chlorhexidine gluconate Drugs 0.000 title claims abstract description 15
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 20
- KUXUALPOSMRJSW-IFWQJVLJSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 KUXUALPOSMRJSW-IFWQJVLJSA-N 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 9
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 claims description 6
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 4
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 3
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 3
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 3
- 239000013008 thixotropic agent Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004088 simulation Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 238000000329 molecular dynamics simulation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 239000012457 nonaqueous media Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008866 synergistic binding Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/31—Anhydrous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
Definitions
- the present disclosure relates to chlorhexidine gluconate solubilized in a hydrophobic monoacylglyceride.
- the present disclosure also relates to compositions incorporating such material, as well as methods of preparing such materials.
- the present disclosure provides a composition comprising chlorhexidine gluconate solubilized in a monoacylglyceride having a hydrophilic-lipophilic balance of no greater than 10.
- the monoacylglyceride has a solubility parameter of greater than 10
- the monoacylglyceride has a binding energy to chlorhexidine gluconate of at least 25 kilocalories per mole. In some embodiments, the monoacylglyceride comprises vicinal hydrogen-bonding groups.
- the acyl group of the monoacylglyceride is a C8 to CI 8 acyl group, e.g., glycerol monocaprylate, glycerol monolaurate, glycerol monoisostearate, glycerol monooleate, and combinations thereof.
- the composition comprises no greater than 1 part by weight monoacylglyceride per 1 part by weight chlorhexidine gluconate. In some embodiments, the composition comprises no greater than 0.1 parts by weight water per 1 part by weight chlorhexidine gluconate.
- the present disclosure provides the composition further comprises a carrier.
- the carrier comprises one or more of a hydrophobic vehicle other than a monoacylglyceride, a polymer, and a solvent.
- the composition further comprises a thixotropic agent.
- Chlorhexidine digluconate commonly referred to as “chlorhexidine gluconate” or “CHG”
- CHG is an antimicrobial useful in various applications.
- CHG is often provided as an aqueous solution, in part because CHG may degrade in a non-aqueous composition.
- CHG has been provided in non-aqueous solutions by replacing water with a hydrophilic vehicle.
- U.S. Patent No. 6,458,341 (Rozzi et al., issued October 1, 2002) describes non-aqueous solutions containing CHG and a solubilizing glycol.
- a hydrophobic vehicle is one having a hydrophile/lipophile balance (“HLB”) of no greater than 10.
- HLB hydrophile/lipophile balance
- the compositions comprise at least 5% by weight CHG dissolved in the hydrophobic vehicle based on the combined weight of the CHG and hydrophobic vehicle. In some embodiments, the compositions comprise at least 10%, e.g., at least 15%, or even at least 20% by weight CHG dissolved in the hydrophobic vehicle based on the combined weight of the CHG and hydrophobic vehicle.
- the first method involves lyophilizing CHG, and then dissolving the CHG into the hydrophobic vehicle.
- the second method involves mixing an aqueous CHG solution with a relatively high boiling hydrophobic vehicle, and then pulling a vacuum on the mixture to remove the water.
- the third method involves generating the CHG in situ by reacting gluconolactone, a limited amount of water, and chlorhexidine free base.
- Each method is expected to give a similar final product, i.e., CHG dissolved in a hydrophobic vehicle, but each method has advantages and disadvantages.
- the lyophilization route does not require exposing the CHG to sustained heat, which helps prevent degradation.
- non-aqueous refers to compositions that may contain small amounts of water, e.g., less than 5 wt.%, based on the total weight of the composition. In some embodiments, the compositions contain less than 2 wt.%, e.g., less than 1 wt.%, or even less than 0.1 wt.% water, based on the total weight of the composition.
- the compositions contain little or no hydrophilic vehicle, i.e., vehicles having an HLB of greater than 10.
- water is considered a separate component independent of any hydrophilic vehicles; therefore, the following amounts are exclusive of any water which may be present in the composition.
- the compositions comprise no greater than 2 parts by weight hydrophilic vehicle per 1 part by weight CHG, e.g., no greater than 1 part by weight, no greater than 0.5 part by weight, or even no greater than 0.1 parts by weight hydrophilic vehicle per 1 part by weight CHG.
- compositions comprise no greater than 1 part by weight water per 1 part by weight CHG, e.g., no greater than 0.5 part by weight, no greater than 0.1 part by weight, or even no greater than 0.01 parts by weight water per 1 part by weight CHG.
- Hydrophobic vehicles have an HLB value of no greater than 10. In some embodiments, the hydrophobic vehicle has an HLB value of no greater than 9, e.g., no greater than 7. [0014] Generally, the hydrophobic vehicle is a monoacylglyceride, e.g., 1 -monoacylglycerides having the formula:
- proximate groups refer to groups separated by no more than three carbon atoms, e.g., the 2- monoacylglycerides of Formula II. In some embodiments, the proximate groups may be vicinal, i.e., separated by two carbon atoms, e.g., the 1 -monoacylglycerides of Formula I.
- the acyl group of the monoacylglyceride is a C8 to CI 8 acyl group.
- the R-group of the acyl group is linear. In some embodiments, the R-group is branched. In some embodiments, the R-group is saturated. In some embodiments, the R-group is unsaturated.
- monoacylglycerides are available as a mixture containing a range of acyl group chain lengths. Exemplary monoacylglycerides include, e.g., glycerol monocaprylate, glycerol monolaurate, glycerol monoisostearate, glycerol monooleate, and combinations thereof. Often such materials are commercially available as mixtures containing both the 1 -monoacylglyceride and the 2- monoacylglyceride.
- Table 1 Vehicles with ester groups providing good CHG solubility.
- HLB values were calculated using the method of Griffin (Griffin WC; J. Soc. of Cosmetic Chemists 5, 259 (1954)) (the "HLB Method”). In this method,
- E is the weight percent of oxyethylene content and P is the weight percent of polyhydric alcohol content (glycerol, sorbitol, etc).
- P polyhydric alcohol content
- glycerol segments with two hydroxyl groups, glycerol segments with one hydroxyl group, and hydroxyl-containing segments of any additional polyhydric molecules were included in the definition of P.
- HLB HLB
- Other methods of calculating HLB are available and may be required when determining the HLB value for compounds lacking both E and P groups, as defined above. While the calculated value of HLB may vary depending on the method used, the trends and relative hydrophobicity of materials are expected to be similar.
- Solubility Parameter Method Solubility parameters were computed via molecular dynamics simulations using the general procedures as described by Belmares et al. (Belmares, M.;
- Binding Energy Method Binding energies were computed using quench molecular dynamics simulations employing QEq charges (Rappe, A.K.; Goddard, W.A.; J. Phys. Chem. 95, 3358 (1991)) and the Dreiding Force Field (Mayo, S.L., Olafson, B.D., Goddard, W.A.; J. Phys. Chem. 94, 8897 (1990)) as implemented in Materials Studio Software (Materials Studio, Accelrys, Software Inc., 10188 Telesis Court, Suite 100, San Diego, CA 92121). Multiple independent simulations were carried out for each vehicle / CHG pair.
- HBN Hydrogen Bonding Number
- compositions may include a carrier in addition to the
- the carrier may comprise another hydrophobic vehicle.
- the carrier may comprise a polymer.
- the carrier may comprise a solvent.
- the carrier may comprise a thixotropic agent, i.e., an agent which renders the composition shear thinning.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261694080P | 2012-08-28 | 2012-08-28 | |
PCT/US2013/056802 WO2014035971A2 (en) | 2012-08-28 | 2013-08-27 | Chlorhexidine gluconate solubilized in a hydrophobic monoacylglyceride |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2890362A2 true EP2890362A2 (en) | 2015-07-08 |
EP2890362B1 EP2890362B1 (en) | 2020-11-11 |
Family
ID=49151333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13759935.3A Active EP2890362B1 (en) | 2012-08-28 | 2013-08-27 | Chlorhexidine gluconate solubilized in a hydrophobic monoacylglyceride |
Country Status (9)
Country | Link |
---|---|
US (1) | US20150238444A1 (en) |
EP (1) | EP2890362B1 (en) |
JP (1) | JP6158928B2 (en) |
CN (1) | CN104684536B (en) |
AU (1) | AU2013308992B2 (en) |
BR (1) | BR112015004178A2 (en) |
CA (1) | CA2882964A1 (en) |
MX (1) | MX367220B (en) |
WO (1) | WO2014035971A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010080936A2 (en) | 2009-01-07 | 2010-07-15 | Entrotech, Inc. | Chlorhexidine-containing antimicrobial laminates |
US20150328360A1 (en) | 2012-08-28 | 2015-11-19 | 3M Innovative Properties Company | Chlorhexidine gluconate compositions, resin systems and articles |
US11039615B2 (en) | 2014-04-18 | 2021-06-22 | Entrotech Life Sciences, Inc. | Methods of processing chlorhexidine-containing polymerizable compositions and antimicrobial articles formed thereby |
WO2017160785A1 (en) | 2016-03-18 | 2017-09-21 | 3M Innovative Properties Company | Adhesive compositions with (meth) acrylic-based block copolymers |
CN113164791B (en) * | 2018-11-30 | 2024-05-17 | 舒万诺知识产权公司 | Topical antimicrobial microemulsions containing fluorescent substances |
EP4007621A1 (en) | 2019-08-01 | 2022-06-08 | 3M Innovative Properties Company | An antimicrobial device for an insertion needle |
US20240083139A1 (en) | 2019-11-04 | 2024-03-14 | 3M Innovative Properties Company | A reinforced adhesive substrate |
US20220387226A1 (en) | 2019-11-20 | 2022-12-08 | 3M Innovative Properties Company | Medical tapes with high optical clarity when over-taped |
JP2023552590A (en) | 2020-12-11 | 2023-12-18 | スリーエム イノベイティブ プロパティズ カンパニー | Perforated tape for medical applications |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1599159A (en) * | 1977-02-08 | 1981-09-30 | Roussel Lab Ltd | Pharmaceutical compositions containing chlorhexidine |
JPH02140167A (en) * | 1988-11-22 | 1990-05-29 | Saraya Kk | Composition for disinfecting hand and finger |
JPH0399010A (en) * | 1989-09-13 | 1991-04-24 | Taisho Pharmaceut Co Ltd | Pharmaceutical composition |
US5093109A (en) * | 1990-04-04 | 1992-03-03 | Chanel, Inc. | Cosmetic composition |
US6458341B1 (en) * | 1998-06-04 | 2002-10-01 | 3M Innovative Properties Company | Devices with coatings containing chlorhexidine gluconate, compositions and methods |
US20030031694A1 (en) * | 2001-04-20 | 2003-02-13 | 3M Innovative Properties Company | Controlled release particles |
DE20204160U1 (en) * | 2002-03-14 | 2002-07-04 | Koehler Pharma Gmbh | Care means |
AU2003282358A1 (en) * | 2002-11-21 | 2004-06-15 | J.P.M.E.D. Ltd. | Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil |
US20050245738A1 (en) * | 2004-05-03 | 2005-11-03 | Lupin Ltd | Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof |
DE602005001295T2 (en) * | 2004-06-08 | 2008-01-31 | Shiseido Co. Ltd. | Cosmetic composition containing a specific terpolymer |
US20060205838A1 (en) * | 2005-03-10 | 2006-09-14 | Velamakanni Bhaskar V | Hardenable antimicrobial dental compositions and methods |
JP2007217394A (en) * | 2006-02-16 | 2007-08-30 | I-Nage:Kk | Pharmaceutical composition |
MX2009004246A (en) * | 2006-10-27 | 2009-05-14 | 3M Innovative Properties Co | Antimicrobial compositions. |
-
2013
- 2013-08-27 WO PCT/US2013/056802 patent/WO2014035971A2/en active Application Filing
- 2013-08-27 US US14/424,198 patent/US20150238444A1/en not_active Abandoned
- 2013-08-27 CA CA2882964A patent/CA2882964A1/en not_active Abandoned
- 2013-08-27 EP EP13759935.3A patent/EP2890362B1/en active Active
- 2013-08-27 BR BR112015004178A patent/BR112015004178A2/en active Search and Examination
- 2013-08-27 AU AU2013308992A patent/AU2013308992B2/en not_active Ceased
- 2013-08-27 MX MX2015002542A patent/MX367220B/en active IP Right Grant
- 2013-08-27 JP JP2015529929A patent/JP6158928B2/en not_active Expired - Fee Related
- 2013-08-27 CN CN201380045403.1A patent/CN104684536B/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO2014035971A3 * |
Also Published As
Publication number | Publication date |
---|---|
CA2882964A1 (en) | 2014-03-06 |
AU2013308992A1 (en) | 2015-03-12 |
JP2015526518A (en) | 2015-09-10 |
CN104684536B (en) | 2018-01-12 |
BR112015004178A2 (en) | 2017-07-04 |
WO2014035971A2 (en) | 2014-03-06 |
MX367220B (en) | 2019-08-09 |
WO2014035971A3 (en) | 2014-10-30 |
JP6158928B2 (en) | 2017-07-05 |
AU2013308992B2 (en) | 2016-06-23 |
CN104684536A (en) | 2015-06-03 |
EP2890362B1 (en) | 2020-11-11 |
US20150238444A1 (en) | 2015-08-27 |
MX2015002542A (en) | 2015-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013308992B2 (en) | Chlorhexidine gluconate solubilized in a hydrophobic monoacylglyceride | |
EP1756226B1 (en) | Silicone vesicles | |
DE102014213507A1 (en) | Platinum-containing composition | |
US8569218B2 (en) | Cleaning composition containing polymer microemulsion | |
JP3854524B2 (en) | Oil-soluble component stabilizing composition, cosmetic containing the composition, and method for stabilizing oil-soluble component | |
US5582813A (en) | Iodine-containing fluorocarbon contrast agents | |
JP2016534028A (en) | Foamable alcohol composition containing branched foaming surfactant | |
CA3172869A1 (en) | Ionic liquid, solvent, preparation, and transdermally absorbable agent | |
CA2933001C (en) | Siloxane-containing phospholipids, compositions and uses thereof | |
EP2138153A1 (en) | Method for production of pearlescent composition | |
EP2885353B1 (en) | Method for producing silicone emulsions | |
JPH11500413A (en) | Paramagnetic complexes of N-alkyl-N-hydroxylamides of organic acids and emulsions containing them for magnetic resonance imaging (MRI) | |
KR100710043B1 (en) | Colloid water-soluble detergent composition comprising palm oleic acid and tocopherol and the producing method thereof | |
CN109528656B (en) | Drug carrier with slow release and protection effects on curcumin, and preparation method and application thereof | |
KR20170117771A (en) | Cosmetic composition containing phenoxyethanol | |
JP2003146872A (en) | Lipid dispersion composition and external preparation for skin | |
CN106137787A (en) | Emulsification composition of reduced coenzyme Q 10 and preparation method thereof | |
JP6122646B2 (en) | Topical skin preparation | |
KR102633521B1 (en) | Method for preparing antiseptic emulsifier based on polyglyceryl-n fatty acid ester | |
EP2066301B1 (en) | Injectable pharmaceutical nimesulide solutions | |
US20090171012A1 (en) | Silicone Vesicles | |
KR100508832B1 (en) | Zinc pyrithione dispersion and shampoo composition | |
JP2022035658A (en) | Aromatic aqueous composition | |
JP2008266324A (en) | Liposome composition and external preparation for skin containing liposome composition | |
CN1899620A (en) | Micro emulsion substance for cosmetics and medicine and its preparing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150303 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170425 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 8/43 20060101ALI20200513BHEP Ipc: A61P 31/04 20060101ALI20200513BHEP Ipc: A61K 47/14 20170101ALI20200513BHEP Ipc: A61Q 19/00 20060101ALI20200513BHEP Ipc: A61K 31/155 20060101ALI20200513BHEP Ipc: A61K 8/37 20060101AFI20200513BHEP Ipc: A61K 9/08 20060101ALI20200513BHEP |
|
INTG | Intention to grant announced |
Effective date: 20200528 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1332774 Country of ref document: AT Kind code of ref document: T Effective date: 20201115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013073986 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20201111 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1332774 Country of ref document: AT Kind code of ref document: T Effective date: 20201111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210211 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210311 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210211 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210311 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013073986 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20210812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602013073986 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210831 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210827 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210311 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210827 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210827 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210827 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220301 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130827 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201111 |